LYEL
Lyell Immunopharma Inc
9.30$
-1.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.7% | -7.4% | -5.8% | -5.3% | -20.7% | -12.4% | -10.3% | +5.8% | -16.6% | +3.1% | -11.3% | |
| – | -5.5% | -3.7% | -6.4% | -10.0% | -15.7% | -18.6% | -8.7% | +16.3% | -20.5% | +2.4% | -20.1% | |
| – | -49.1% | -13.7% | +6.2% | -24.8% | +5.3% | +14.0% | -17.9% | +25.1% | -51.3% | +50.8% | -19.6% | |
| – | -5.1% | -3.6% | -6.7% | -10.3% | -15.9% | -18.7% | -8.1% | +15.5% | -22.7% | +2.8% | -19.7% | |
| – | -2.4% | -4.2% | -3.8% | +1.0% | +22.0% | -13.7% | -7.2% | -8.9% | +16.5% | -16.2% | +0.5% | |
| – | -1.6% | -6.3% | -4.6% | +8.5% | +60.5% | -23.2% | -10.6% | -13.6% | +55.0% | -25.2% | +7.9% | |
| – | +3.5% | +6.3% | +3.5% | +3.4% | +11.8% | +3.3% | +3.3% | +3.3% | +3.2% | +3.2% | – | |
| – | +10.4% | +1.6% | -14.2% | -14.4% | +49.2% | -30.5% | -9.4% | -24.0% | +12.7% | +89.0% | -29.1% | |
| – | -6.1% | -7.9% | -6.1% | -6.3% | -27.9% | -12.1% | -11.2% | +10.1% | -24.6% | +10.3% | -14.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.7% | +0.5% | +0.5% | +0.4% | +4.0% | +10.7% | +0.3% | +23.5% | -6.4% | +28.0% | +6.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.